These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23878113)

  • 21. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
    Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
    Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Pal SK; Pegram M
    Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. For investigational targeted drugs, combination trials pose challenges.
    Goldman B
    J Natl Cancer Inst; 2003 Dec; 95(23):1744-6. PubMed ID: 14652234
    [No Abstract]   [Full Text] [Related]  

  • 26. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 27. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N; Belani C
    Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
    [No Abstract]   [Full Text] [Related]  

  • 29. [Personalised treatment of lung cancer].
    Ullrich RT; Zander T; Wolf J; Hallek M
    Dtsch Med Wochenschr; 2012 Oct; 137(42):2179-80. PubMed ID: 23055362
    [No Abstract]   [Full Text] [Related]  

  • 30. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 31. [HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
    Mihály Z; Gyõrffy B
    Magy Onkol; 2013 Sep; 57(3):147-56. PubMed ID: 24107820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
    Gori S; Montemurro F; Spazzapan S; Metro G; Foglietta J; Bisagni G; Ferzi A; Silva RR; Gamucci T; Clavarezza M; Stocchi L; Fabi A; Cognetti F; Torrisi E; Crivellari D
    Ann Oncol; 2012 Jun; 23(6):1436-41. PubMed ID: 22039084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor inhibition in solid tumours.
    Ganti AK; Potti A
    Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
    Noguchi E; Shimizu C
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular selection trumps clinical selection.
    Shepherd FA
    J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
    [No Abstract]   [Full Text] [Related]  

  • 36. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
    Ren YL; Sheng J; Zhou XY; Fang Y; Pan HM
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):152-153. PubMed ID: 30862147
    [No Abstract]   [Full Text] [Related]  

  • 39. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.
    Fedele P; Orlando L; Schiavone P; Ciccarese M; Forcignanò RC; Calvani N; Marino A; Nacci A; Sponziello F; Mazzoni E; Rizzo P; Lorusso V; Cinieri S
    J Chemother; 2013 Dec; 25(6):369-75. PubMed ID: 24392943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.